3BDO

Additional information:
3BDO is a new mTOR activator which can also inhibit autophagy.|Product information|CAS Number: 890405-51-3|Molecular Weight: 327.33|Formula: C18H17NO5|Chemical Name: 3-benzyl-5-[(2-nitrophenoxy)methyl]oxolan-2-one|Smiles: [O-][N+](=O)C1=CC=CC=C1OCC1CC(CC2C=CC=CC=2)C(=O)O1|InChiKey: AXPZIVKEZRHGAS-UHFFFAOYSA-N|InChi: InChI=1S/C18H17NO5/c20-18-14(10-13-6-2-1-3-7-13)11-15(24-18)12-23-17-9-5-4-8-16(17)19(21)22/h1-9,14-15H,10-12H2|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO : ≥ 100 mg/mL (305.50 mM) Ethanol : 20 mg/mL (61.10 mM; Need ultrasonic)|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|Phosphorylation of RPS6KB1 and EIF4EBP1 is significantly increased by 3BDO with vector alone but suppressed with FKBP1A overexpression. Rapamycin fails to decrease the phosphorylation of MTOR and RPS6KB1 in the presence of 3BDO. 3BDO suppresses the increase in MAP1LC3B puncta induced with rapamycin. 3BDO also inhibits the effect of rapamycin in HUVECs. The phosphorylation of Ser residues is decreased in HUVECs treated with 10 μM rapamycin, and 60 μM 3BDO reverses the phosphorylation.{{Trastuzumab (anti-HER2)} MedChemExpress|{Trastuzumab (anti-HER2)} EGFR|{Trastuzumab (anti-HER2)} TGF-beta/Smad|{Trastuzumab (anti-HER2)} Protocol|{Trastuzumab (anti-HER2)} Formula|{Trastuzumab (anti-HER2)} manufacturer} The results show that 3BDO suppresses the increased MAP1LC3B puncta number, MAP1LC3B-II level and decreased SQSTM1 protein level induced by rapamycin.{{Vonoprazan} MedChemExpress|{Vonoprazan} Bacterial|{Vonoprazan} Biological Activity|{Vonoprazan} In Vivo|{Vonoprazan} custom synthesis|{Vonoprazan} Epigenetic Reader Domain} 3BDO could dose- and time-dependently decrease FLJ11812 level in HUVECs.PMID:32239879 Overexpression of FLJ11812 reverses the inhibition of autophagy induced by 3BDO.|In Vivo:|Immunofluorescence assay reveals that 3BDO treatment increases the level of p-p70S6K and decreases the protein level of ATG13 in plaque endothelium of mice. 3BDO does not affect the phosphorylation of mTOR direct downstream targets p70S6K and 4EBP1. As compare with controls, apoE-/- mice show inhibited endothelium autophagy and apoptosis with 3BDO treatment, so 3BDO protects against endothelium injury in atherosclerosis. 3BDO treatment stabilizes established atherosclerotic lesions in apoE-/- mice. In apoE-/-mice, as compare with controls, with 3BDO treatment, the serum level of IL-6 and IL-8 is significantly decreased.|References:|Ge D, et al. Identification of a novel MTOR activator and discovery of a competing endogenous RNA regulating autophagy in vascular endothelial cells. Autophagy. 2014 Jun;10(6):957-71.Peng N, et al. An activator of mTOR inhibits oxLDL-induced autophagy and apoptosis in vascular endothelial cells and restricts atherosclerosis in apolipoprotein E-/- mice. Sci Rep. 2014 Jul 1;4:5519.Products are for research use only. Not for human use.|